Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors [Yahoo! Finance]
Lucid Diagnostics Inc. (LUCD)
Company Research
Source: Yahoo! Finance
NEW YORK Feb. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that it has contracted with the World Trade Center Health Program ("WTCHP") to provide the EsoGuard ® Esophageal DNA test as a covered benefit to the more than 120,000 responders and survivors who participate in the program. The WTCHP provides medical monitoring and treatment to those directly affected by the 9/11 terrorist attacks, including members of the Fire Department of the City of New York (FDNY) and other emergency responders at the World Trade Center, recovery and cleanup workers and those who were in the New York City Disaster Area on September 11, 2001 , or in the months that followed. EsoGuard is now reimbursable at per test prescribed by clinicians at one of WTCHP's Clinical Centers of Excellence. "We are gra
Show less
Read more
Impact Snapshot
Event Time:
LUCD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUCD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUCD alerts
High impacting Lucid Diagnostics Inc. news events
Weekly update
A roundup of the hottest topics
LUCD
News
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024PR Newswire
- Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing [Yahoo! Finance]Yahoo! Finance
- Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer TestingPR Newswire
- Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness MonthPR Newswire
- Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.MarketBeat
LUCD
Sec Filings
- 5/2/24 - Form 8-K
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form ARS
- LUCD's page on the SEC website